Liver News and Research

RSS

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

Researchers to test Radio-embolisation technique in patients with bowel cancer

Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy.

24 Feb 2010

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Lack of knowledge and awareness impeding efforts to control HBV and HCV

A recent report by the Institute of Medicine (IOM) confirmed that 3.5 to 5.3 million people (1-2 % of the U.S. population) have chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Despite efforts by federal, state and local government agencies to control and prevent these diseases, they remain a serious public health concern. The major factor impeding efforts to control HBV and HCV is lack of knowledge and awareness among health care providers, social service professionals, members of the public, and policy-makers.

24 Feb 2010

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.

24 Feb 2010

Mouse study provides new way to test novel therapies for liver infections

How do you study-and try to cure in the laboratory-an infection that only humans can get? A team led by Salk Institute researchers does it by generating a mouse with an almost completely human liver.

24 Feb 2010

Researchers study how laser-induced ultrasound could help identify the stage of melanoma

Knowing the stage of a patient's melanoma is important when choosing the best course of treatment. When the cancer has progressed to the lymph nodes, a more aggressive treatment is needed. Examining an entire lymph node for cancer takes much effort and time; a new technique might help make the process more efficient.

24 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Trial for lawsuit against Anthem Blue Cross begins in California

The insurer "refused to pay for" customer Ephram Nehme "to get a liver transplant in Indiana because the company wanted to save money, a lawyer for the patient told jurors Monday," the Los Angeles Times reports. "But a lawyer for the state's largest for-profit insurer argued that the patient, Ephram Nehme, was not sick enough to qualify for an exception to his policy's requirement that transplants be performed in Blue Cross-contracted hospitals in California.

23 Feb 2010

First Edition: February 23, 2010

Today's headlines focus on President Obama's revamped health reform proposal, what it includes and how Democrats, Republicans and the insurers are reacting to it.

23 Feb 2010

Role of behavioral health in pediatric IBD: NIHCD awards $500,000 grant to further study

The National Institutes of Health has awarded a two-year development grant to researchers with Hasbro Children's Hospital and the Bradley Hasbro Children's Research Center to better understand the role behavioral health plays in pediatric inflammatory bowel disease (IBD), a condition that causes chronic and painful inflammation in the gastrointestinal tract.

23 Feb 2010

Genetics associated with DILI and SSR: FDA and SAEC complete third release of data

The U.S. Food and Drug Administration and the International Serious Adverse Event Consortium (SAEC) today announced the third release of data on the genetic basis of drug-induced liver injury (DILI) and serious skin reactions (SSRs).

22 Feb 2010

Insurer allegedly, automatically denies request for liver transplant: Trial commences on 22nd Feb

A trial beginning Monday targeting the nation's largest health insurer, WellPoint Inc., and its California subsidiary, Anthem Blue Cross, for allegedly automatically denying requests for out-of-network liver transplants will help shed light on the need for stronger health reform than is currently being considered, according to Consumer Watchdog. The group urged President Obama, White House representatives, and the national news media to follow the trial.

22 Feb 2010

Brain and tissue sample repository to help advance understanding and treatment of psychiatric diseases

Johns Hopkins Children's Center neurovirologist Robert Yolken, M.D., and collaborators from the Stanley Medical Research Institute have developed a large repository of brain and tissue samples to advance the understanding and treatment of bipolar disorder, major depression and schizophrenia.

20 Feb 2010

Most genetic abnormalities shared across multiple cancers

An international team of researchers has created a genome-scale map of 26 different cancers, revealing more than 100 genomic sites where DNA from tumors is either missing or abnormally duplicated compared to normal tissues. The study, the largest of its kind, finds that most of these genetic abnormalities are not unique to one form of cancer, but are shared across multiple cancers. The work appears in the February 18 issue of the journal Nature.

19 Feb 2010

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

Scientists at the Johns Hopkins Kimmel Cancer Center have used data from the whole genome sequencing of cancer patients to develop individualized blood tests they believe can help physicians tailor patients' treatments. The genome-based blood tests, believed to be the first of their kind, may be used to monitor tumor levels after therapy and determine cancer recurrence.

19 Feb 2010

Cellular metabolism plays a key role in cancer development

It is not unusual to hear people blame their metabolism after gaining a few pounds. But changes in metabolism - the process that shapes how our bodies turn food into energy -- can have much more sinister effects than making it hard to fit into your favorite jeans.

19 Feb 2010

Report examines how medical technology changes state of health care

Federal researchers Wednesday released a report that examines how medical technology is changing the state of health care.

19 Feb 2010

Liver News and Research

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Researchers to test Radio-embolisation technique in patients with bowel cancer

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Lack of knowledge and awareness impeding efforts to control HBV and HCV

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Mouse study provides new way to test novel therapies for liver infections

Researchers study how laser-induced ultrasound could help identify the stage of melanoma

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Trial for lawsuit against Anthem Blue Cross begins in California

First Edition: February 23, 2010

Role of behavioral health in pediatric IBD: NIHCD awards $500,000 grant to further study

Genetics associated with DILI and SSR: FDA and SAEC complete third release of data

Insurer allegedly, automatically denies request for liver transplant: Trial commences on 22nd Feb

Brain and tissue sample repository to help advance understanding and treatment of psychiatric diseases

Most genetic abnormalities shared across multiple cancers

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

Cellular metabolism plays a key role in cancer development

Report examines how medical technology changes state of health care

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News